


 Cite this: *RSC Adv.*, 2025, 15, 35003

Design, synthesis, and *in silico* studies of new benzofuran–pyrazole hybrids as multi-kinase inhibitors with potential antiproliferative activity

 Somaia S. Abd El-Karim,^a Yasmin M. Syam,^a Reham M. Abdelkader,^b Mohamed K. El-Ashrey^{cd} and Manal M. Anwar^{ba}

A new series of benzofuran–pyrazole-based analogues, conjugated with different substituted aromatic and heterocyclic ring systems featuring the pharmacophoric fragments of protein kinase suppressors, **3a–d** and **4a–d** was synthesized as potential antiproliferative agents. All the new analogues were selected by the NCI to screen their antiproliferative activity against sixty human cancer cell lines (NCI60). The 1*H*-benzo[*d*]imidazole derivative **3d** demonstrated the highest percentage inhibition for various cancer cell lines and advanced to the five-dose assay. It showed potent anti-proliferative activity against various types of cancer lines with GI₅₀ values ranging from 0.33 to 4.87 μM and LC₅₀ values exceeding 100 μM against the majority of the tested cell lines, confirming its non-lethal effects. Additionally, **3d** exhibited multi-targeting PK-suppression activity against B-Raf (V600E), c-Met, Pim-1, EGFR (WT), and VEGFR-2, with IC₅₀ values of 0.078 ± 0.004, 0.405 ± 0.017, 1.053 ± 0.046, 0.177 ± 0.007 and 0.275 ± 0.011 μg mL⁻¹, respectively. Moreover, **3d** caused cell cycle arrest at the G₀–G₁ phase besides early and late apoptosis in MCF-7 cancer cells. *In silico* molecular docking and ADMET studies were performed on **3d** to determine its expected binding interactions with the key regions in the kinase domains, as well as to ascertain its risks of human toxicity, drug-likeness traits, and oral bioavailability.

 Received 23rd January 2025
 Accepted 25th July 2025

DOI: 10.1039/d5ra00553a

rsc.li/rsc-advances

1. Introduction

The development of effective and specifically targeted anti-cancer medicines is the primary goal in cancer therapeutic approaches. Chemotherapy continues to be the most essential means for treating cancer, even with the availability of several clinical cancer treatment techniques, including laser therapy, stem-cell transplantation, radiotherapy, immunotherapy, hormonal therapy, and surgery.^{1,2}

However, traditional cancer chemotherapeutic agents lack selectivity, resulting in toxicity to normal cells due to the similarities between cancer and normal human cells. Another emerging challenge in antitumor therapy is the development of tumor cells' resistance to anticancer drugs.^{3,4} In addition, cancer is a heterogeneous disease, and thus, a multitargeted treatment may provide greater therapeutic effectiveness and a lower adverse effect profile than mono-targeted treatment.^{5,6}

However, using more than one medication in cancer treatment leads to the simultaneous blocking of different targets, which might result in harmful drug–drug interactions and drug resistance. Therefore, experts believe that employing a single medication capable of influencing multiple targets presents a distinct strategy for surmounting previous obstacles.^{7,8}

In humans, protein kinases (PKs) comprise the fifth-largest protein family,^{9,10} which act by transferring the terminal phosphate group of an ATP molecule to a substrate protein.^{9,11,12} These PKs are categorized as tyrosine kinases; serine/threonine kinases; or dual-specificity kinases, such as MEK1 and MEK2, which can catalyze the phosphorylation of tyrosine or threonine on the target proteins.^{9,10} As a result, regulatory disturbance in PKs causes a variety of diseases, including cancer.^{13,14} Thus, blocking PKs is a potential tactic to mitigate the interruptions they cause.^{9,15} PK inhibitors are a well-known type of targeted chemotherapy used in oncology, and they mainly affect the microenvironment and signaling pathways of cancer cells while having few negative effects on healthy cells.^{16–18}

The surface of cancerous cells overexpresses a class of tyrosine kinases known as human epithelial growth factor receptors (EGFR). Given that it is implicated in the proliferation, migration, differentiation, apoptosis, and angiogenesis of cancer cells, EGFR (HER1) is one of the most significant cancer treatment targets.^{19–22} Due to T790M, L858R, and C797S mutations in the ATP binding pocket of EGFR, predominant drug

^aDepartment of Therapeutic Chemistry, National Research Centre, El-Bohouth St., 12262, Cairo, Egypt. E-mail: ssabdelkarim@gmail.com; manal.hasan52@live.com

^bDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt

^cPharmaceutical Chemistry Department, Faculty of Pharmacy, Cairo University, Kasr Elini St., Cairo 11562, Egypt

^dMedicinal Chemistry Department, Faculty of Pharmacy, King Salman International University (KSU), South Sinai 46612, Egypt






Fig. 1 Examples of various benzofuran- and pyrazole-based candidates with anticancer activity targeting different protein kinases.

resistance and limited drug efficacy were detected in 50% of cancer patients. Accordingly, various generations of EGFR inhibitors have been developed to overcome these resistant tumor clones. However, despite the excellent characteristics of third-generation EGFR inhibitors such as WZ4002, rociletinib and osimertinib (AZD9291), they exhibited several adverse effects in clinical application, including diarrhea, rash, decreased appetite and cardiotoxicity.²³⁻²⁸ Accordingly, there is still a great demand to develop new EGFR inhibitors with high selectivity^{19,20,29} (Fig. S24, SI).

The vascular endothelial growth factor (VEGF) family and hepatocyte growth factor receptor (HGFR), which is also known

as c-Met (c-mesenchymal epithelial transition factor), are receptor tyrosine kinases (RTKs). Enhanced vascular permeability, endothelial growth, invasion, migration, cell proliferation, differentiation, apoptosis, and morphogenesis are primarily triggered by VEGFR-2 and c-Met. Moreover, VEGFR-2 is critical in pathological and physiological angiogenesis. Therefore, experts believe that directly stopping the intracellular kinase domains of VEGFR-2 and c-Met by competing with the ATP-binding sites is the most effective way to stop tumor growth^{15,29-49} (SI, SI).

Three serine/threonine kinases (Pim-1, Pim-2, and Pim-3) make up the provirus integration in Maloney (Pim) kinases






Fig. 2 Hypothetical pharmacophoric characteristics of the newly synthesized compounds.

family. They play a crucial role in controlling several biological processes, such as the cell cycle, apoptosis, and proliferation.⁵⁰ Given that PIM kinases are expressed in a variety of solid and hematological malignancies and are essentially absent in benign tumors, they have been shown to be effective targets for anticancer drugs with low toxicity.⁵¹ Most Pim inhibitor investigations have focused on Pim-1 inhibitors because of the low K_m of Pim-2 for ATP, which is 100-times lower than that of Pim-1 and Pim-3 (S1, SI).^{52,53} Additionally, the ERK-MAPK pathway is regulated by serine/threonine kinases called BRAF. Due to the replacement of valine for glutamic acid at position 600, the BRAF gene (V600E) has the highest frequency of BRAF mutations in human malignancies. According to recent studies, BRAF suppression marks a new era in the therapeutic management of human cancer⁵⁴ (S1, SI).

The benzofuran nucleus is a useful building block in the realm of pharmaceutical discovery and development due to its intriguing biological characteristics, especially in the field of cancer treatment. This scaffold has various approaches to mediate its anticancer action, such as anti-angiogenesis, anti-tubulin polymerization, and inhibition of carbonic anhydrases, EGFR, and different protein kinases.^{16,55,56} Fig. 1 demonstrates various examples of benzofuran-based derivatives with significant anticancer activity targeting different protein kinases.^{16,56–58}

Azoles, *viz.*, pyrazoles and pyrazolines, constitute valuable building blocks in medicinal chemistry.¹⁵ Presently, different commercially available pyrazole-containing drugs are used to treat various types of cancers (Fig. 1).^{59–62} Several studies demonstrated that pyrazole-based compounds exhibit *in vitro* and *in vivo* antitumor activity by inhibiting various enzymes such as topoisomerase II, EGFR, MEK, VEGFR, GGT1, microtubule, and HDACs.^{59–62}

1.1. Rationale of molecular design

Molecular hybridization is an effective technique in the realm of drug discovery and development, where this approach aims to conjugate two or more pharmacophoric or bioactive subunits covalently into novel hybrid molecules. In comparison to their parent drugs, these newly created hybrids often exhibit better affinity and efficacy, improved pharmacokinetic and pharmacodynamic properties, and the ability to engage in dual or multiple modes of action, with diminished undesirable side effects and reduced likelihood of drug–drug interactions and emergence of drug resistance or proliferation.^{63–67}

The majority of studies that link the molecular structures of various heterocyclic-based derivatives and their ability to suppress protein kinases have revealed that these compounds have four main characteristic features, a central aromatic heterocyclic scaffold, which serves as a hydrogen bond acceptor (HBA) to interact with the adenine binding pocket of the target enzyme, an aryl ring, such as substituted phenyl, aromatic, and fused aromatic heterocyclic cores, a linker bridge that might be a linear chain or a heterocyclic moiety (where the length and number of hydrogen donor and/or acceptor groups can be altered), and a hydrophobic tail, such as a phenyl ring, which occupies the hydrophobic allosteric pocket through multiple hydrophobic interactions^{15,68} (Fig. 2).

As a result of our curiosity in the field of drug discovery and based on the promising anticancer potency of the benzofuran and pyrazole ring systems, we have utilized the molecular hybridization technique to design and create new compounds that possess the key pharmacophoric characteristics of protein kinase suppressors with multi-targeting kinase inhibition and anticancer potential. The new congeners are based on



a benzofuran-pyrazole scaffold as the main heteroaromatic system to interact with the adenine binding pocket of the target enzyme tethered with various substituted aromatic and heterocyclic rings *via* pyrazoline rings **3** and **4** (Fig. 2). The degree of hydrophobicity and releasing/withdrawing capacities of the substituents on the pyrazoline ring produced various impacts on inhibitory action against the target protein kinase and the anticancer activity.

The National Cancer Institute (NCI) tested all the new target candidates for their anticancer activity against a set of sixty cancer cell lines. Moreover, the impact of the most promising compound was further evaluated *in vitro* against multi-kinases, B-Raf (V600E), c-Met, Pim-1, EGFR (WT), and VEGFR-2 enzymes, in addition to the cancer cell cycle and the capacity to trigger apoptosis to reveal the anticipated mechanism of anti-proliferative activity.

In silico molecular docking investigation was also carried out to find out the expected interaction model of the most promising analogue with the active sites of the above-mentioned kinases. Furthermore, an *in silico* ADMET study was performed to ascertain its risks of human toxicity, drug-likeness traits, and oral bioavailability.

2. Materials and methods

2.1. Chemistry

2.1.1. General remarks. The chemicals that were involved in the synthesis of the target compounds, as well as for biological evaluation were obtained from commercial suppliers. Precoated silica gel 60 F₂₄₅ aluminium plates (Merck) were used to follow the progress of the chemical reaction. Uncorrected melting points were measured on an Electrothermal 9100 apparatus. Spectral and elemental analyses of the synthesized compounds were performed in the Micro Analytical Labs, National Research Centre, Cairo, Egypt. IR spectra (4000–400 cm⁻¹) were recorded on an FT/IR-4100 Jasco-Japan Fourier transform infrared spectrophotometer. ¹H NMR and ¹³C NMR (DMSO-*d*₆) spectra were measured at 400 (100) MHz on Bruker instruments.

2.1.2. General procedure for the synthesis of the target compounds 3-(3-(benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-1-(substituted)-prop-2-en-1-one 2a-d. A mixture of carbaldehyde **1** (2.88 g, 0.01 mol) and the appropriate acetyl derivatives, namely, acetophenone, 4-methoxyacetophenone, 3,4-dimethoxyacetophenone and/or 2-acetyl-1H-benzo[d]imidazole (0.01 mol), in alcoholic sodium hydroxide solution (30 mL, 10%) was stirred for 5 h. The reaction mixture was left overnight at room temperature. The formed precipitate was filtered, washed several times with water, dried and recrystallized from ethanol to give the target compounds **2a-d**, respectively.

2.1.2.1. 3-(5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-3-yl)-1-phenylprop-2-en-1-one (2a). Yield (75%), mp 201–203 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3062 (CH, aromatic), 2916, 2851 (CH-aliphatic), 1632 (C=O), 1601 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 7.35 (t, ³J = 7.18 Hz, 1H, Ar-H), 7.40–7.48 (m, 3H, Ar-H), 7.63 (t, ³J = 7.10 Hz, 4H, Ar-H), 7.71 (t, ³J = 6.48 Hz, ⁴J = 2.32 Hz, 2H, Ar-H), 7.77 (d, ³J = 7.40 Hz, 1H, CH=), 7.94–7.99 (m, 3H, Ar-H),

8.14–8.17 (m, 3H, Ar-H), 9.52 (s, 1H, pyrazole-H4) ppm; ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 105.82, 111.73, 118.96, 119.36, 122.15, 122.86, 124.02, 125.74, 128.08, 128.40, 128.77, 129.30, 129.47, 130.25, 133.60, 134.23, 138.11, 139.19, 143.67, 149.60, 154.80, 189.40 (CO) ppm; MS, *m/z* (%): 390 [M⁺] (38.05), analysis for C₂₆H₁₈N₂O₂ (390.44), calcd% C, 79.98; H, 4.65; N, 7.17 found: % C, 97.75; H, 4.58; N, 7.08.

2.1.2.2. 3-(5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-3-yl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b). Yield (75%), mp 125–126 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3063 (CH, aromatic), 2955, 2832 (CH-aliphatic), 1639 (C=O), 1601 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 3.89 (s, 3H, OCH₃), 7.13 (d, ³J = 8.72 Hz, 2H, Ar-H), 7.35 (t, ³J = 7.18 Hz, 1H, Ar-H), 7.40–7.42 (m, 2H, Ar-H), 7.46 (t, ³J = 7.40 Hz, 1H, Ar-H), 7.63 (t, ³J = 7.92 Hz, 2H, Ar-H), 7.72 (d, ³J = 8.16 Hz, 1H, =CH), 7.77 (d, ³J = 7.28 Hz, 1H, =CH), 7.95–7.99 (m, 3H, Ar-H), 8.09–8.17 (m, 3H, Ar-H), 9.49 (s, 1H, pyrazole-H4) ppm. ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 56.05 (OCH₃), 105.77, 111.73, 114.53, 119.08, 119.34, 122.13, 122.81, 124.01, 125.72, 128.04, 128.41, 129.26, 130.24, 130.90, 131.16, 133.19, 139.20, 143.57, 149.62, 154.78, 163.71, 187.56 (CO) ppm; MS, *m/z* (%): 420 [M⁺] (33.47), analysis for C₂₇H₂₀N₂O₃ (420.47), calcd% C, 77.13; H, 4.79; N, 6.66 found: % C, 77.19; H, 4.83; N, 6.72.

2.1.2.3. 3-(5-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-3-yl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (2c). Yield (75%), mp 175–176 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3063 (CH, aromatic), 2923, 2839 (CH-aliphatic), 1651 (C=O), 1597 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 3.87 (s, 3H, OCH₃), 3.90 (s, 3H, OCH₃), 7.15 (d, ³J = 8.48 Hz, 1H, Ar-H), 7.35 (t, ³J = 7.32 Hz, 1H, Ar-H), 7.40–4.42 (m, 1H, Ar-H), 7.46 (t, ³J = 7.36 Hz, 2H, Ar-H), 7.61–7.65 (m, 3H, Ar-H), 7.71 (d, ³J = 8.12 Hz, 1H, =CH), 7.77 (d, ³J = 7.48 Hz, 1H, =CH), 7.86 (d, ³J = 8.44 Hz, ⁴J = 1.72 Hz, 1H, Ar-H), 7.92–7.93 (m, 1H, Ar-H), 7.97 (d, ³J = 8.76 Hz, 2H, Ar-H), 8.09–8.13 (m, 1H, Ar-H), 9.47 (s, 1H, pyrazole-H4) ppm. ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 56.08 (OCH₃), 56.29 (OCH₃), 105.76, 111.21, 111.36, 111.73, 119.11, 119.39, 122.13, 122.79, 123.54, 124.01, 125.71, 128.03, 128.43, 129.33, 130.24, 131.01, 133.12, 139.24, 143.57, 149.36, 149.69, 153.75, 154.80, 187.47 (CO) ppm; MS, *m/z* (%): 450 [M⁺] (37.06), analysis for C₂₈H₂₂N₂O₄ (450.49), calcd% C, 74.65; H, 4.92; N, 6.22 found: % C, 74.70; H, 4.87; N, 6.38.

2.1.2.4. 1-(1H-Benzo[d]imidazol-2-yl)-3-(5-(benzofuran-2-yl)-1-phenyl-1H-pyrazol-3-yl)prop-2-en-1-one (2d). Yield (75%), mp 222–223 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3244 (NH), 3063 (CH, aromatic), 2924, 2851 (CH-aliphatic), 1655 (C=O), 1582 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 7.33–7.37 (m, 3H, Ar-H), 7.41–7.46 (m, 3H, Ar-H), 7.60 (t, ³J = 7.92 Hz, 2H, Ar-H), 7.72–7.76 (m, 3H, Ar-H), 7.79 (d, ³J = 7.52 Hz, 1H, Ar-H), 8.07 (d, ³J = 7.84 Hz, 2H, Ar-H), 8.18 (d, ³J = 16.0 Hz, 1H, Ar-H), 8.42 (d, ³J = 16.0 Hz, 1H, Ar-H), 9.62 (s, 1H, pyrazole-H4) ppm. ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 106.06, 111.80, 117.52, 118.82, 119.44, 122.16, 122.85, 124.03, 124.69, 125.76, 128.02, 128.43, 129.67, 130.15, 134.59, 139.19, 143.91, 149.52, 149.98, 154.85, 181.59 (CO) ppm; MS, *m/z* (%): 430 [M⁺] (33.63), analysis for C₂₇H₁₈N₄O₂ (430.47), calcd% C, 75.34; H, 4.21; N, 13.02 found: % C, 75.47; H, 4.28; N, 12.95.



2.1.3. General procedure for the synthesis of the target compounds 3-(benzofuran-2-yl)-4-(3-substituted-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole 3a-d. A mixture of chalcones **2a-d** (0.002 mol) and hydrazine hydrate (0.2 mL, 98%) in absolute ethanol was refluxed for 3 h. The precipitate formed during heating was filtered, dried and recrystallized from absolute ethanol to give compounds **3a-d**, respectively.

2.1.3.1. 3-(Benzofuran-2-yl)-4-(3-phenyl-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole (3a). Yield (75%), mp 145–146 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3314 (NH), 3082, 3055 (CH, aromatic), 2920, 2851 (CH-aliphatic), 1597 (C=C), $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 3.04–3.11 (dd, $^2J = 10.4$, $^3J = 16.28$ Hz, 1H, pyrazoline-H4), 3.59–3.65 (dd, $^2J = 10.72$, $^3J = 16.28$ Hz, 1H, pyrazoline-H4), 5.24–5.30 (m, 1H, pyrazoline-H5), 7.28–7.42 (m, 7H, Ar-H), 7.52–7.59 (m, 3H, Ar-H), 7.67–7.72 (m, 3H, Ar-H), 7.93 (d, $^3J = 7.88$ Hz, 2H, Ar-H), 8.64 (s, 1H, pyrazole-H4), 10.21 (s, 1H, NH, D $_2$ O exchangeable) ppm. $^{13}\text{C NMR}$ (100 MHz; DMSO- d_6) δ_{C} 50.50 (pyrazoline-C-4), 55.47 (pyrazoline-C5), 95.99, 104.78, 109.65, 111.77, 118.88, 119.76, 121.78, 123.76, 124.64, 125.22, 126.04, 127.17, 128.76, 128.97, 129.35, 130.12, 130.27, 133.63, 134.00, 139.66, 141.86, 150.04, 154.52, 154.62 (Ar-C) ppm; MS, m/z (%): 390 [M^+] (38.05), analysis for C $_{26}$ H $_{20}$ N $_4$ O (404.47), calcd% C, 77.21; H, 4.98; N, 13.85 found: % C, 77.32; H, 5.03; N, 13.90.

2.1.3.2. 3-(Benzofuran-2-yl)-4-(3-(4-methoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole (3b). Yield (75%), mp 172–173 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3310 (NH), 3078, 3051 (CH, aromatic), 2928, 2835 (CH-aliphatic), 1601 (C=C); $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 3.00–3.07 (dd, $^2J = 10.48$, $^3J = 16.20$ Hz, 1H, pyrazoline-H4), 3.56–3.62 (dd, $^2J = 10.56$, $^3J = 16.24$ Hz, 1H, pyrazoline-H4), 3.78 (s, 3H, OCH $_3$), 5.23 (t, $^3J = 10.52$ Hz, 1H, pyrazoline-H5), 6.95 (d, $^3J = 8.84$ Hz, 2H, Ar-H), 7.28 (t, $^3J = 7.86$ Hz, 1H, Ar-H), 7.32–7.38 (m, 4H, Ar-H), 7.54 (t, $^3J = 7.94$ Hz, 2H, Ar-H), 7.61 (d, $^3J = 8.80$ Hz, 2H, Ar-H), 7.70 (t, $^3J = 7.04$ Hz, 2H, Ar-H), 7.92 (d, $^3J = 7.84$ Hz, 2H, Ar-H), 8.63 (s, 1H, pyrazole-H); MS, m/z (%): 434 [M^+] (35.62), analysis for C $_{27}$ H $_{22}$ N $_4$ O $_2$ (434.50), calcd% C, 74.64; H, 5.10; N, 12.89 found: % C, 74.72; H, 5.23; N, 12.91.

2.1.3.3. 3-(Benzofuran-2-yl)-4-(3-(3,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole (3c). Yield (75%), mp 158–160 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3314 (NH), 3067, 3051 (CH, aromatic), 2920, 2851 (CH-aliphatic), 1597 (C=C); $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 3.02–3.08 (dd, $^2J = 10.32$, $^3J = 16.20$ Hz, 1H, pyrazoline-H4), 3.56–3.62 (dd, $^2J = 10.56$, $^3J = 16.20$ Hz, 1H, pyrazoline-H4), 3.78 (s, 3H, OCH $_3$), 3.79 (s, 3H, OCH $_3$), 5.24 (t, $^3J = 10.42$ Hz, 1H, pyrazoline-H5), 6.95 (d, $^3J = 8.36$ Hz, 1H, Ar-H), 7.13 (d, $^3J = 8.32$, $^4J = 1.68$, 1H, Ar-H), 7.29–7.40 (m, 5H, Ar-H), 7.54 (t, $^3J = 7.92$ Hz, 2H, Ar-H), 7.71 (t, $^3J = 6.92$ Hz, 2H, Ar-H), 7.93 (d, $^3J = 7.84$ Hz, 2H, Ar-H), 8.62 (s, 1H, pyrazole-H4) ppm. $^{13}\text{C NMR}$ (100 MHz; DMSO- d_6) δ_{C} 42.22 (pyrazoline-C4), 55.43 (pyrazoline-C5), 55.85 (OCH $_3$), 55.97 (OCH $_3$), 104.79, 108.83, 111.76, 111.87, 118.87, 119.42, 121.78, 123.76, 124.73, 125.22, 126.50, 127.15, 127.73, 128.77, 130.11, 139.67, 141.86, 149.17, 149.75, 150.07, 150.29, 154.51 (Ar-C) ppm; MS, m/z (%): 464 [M^+] (33.47), analysis for C $_{28}$ H $_{24}$ N $_4$ O $_3$ (464.53), calcd% C, 72.40; H, 5.21; N, 12.06 found: % C, 72.48; H, 5.36; N, 11.86.

2.1.3.4. 3-(Benzofuran-2-yl)-4-(3-(1H-benzolimidazol-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)-1-phenyl-1H-pyrazole (3d). Yield (75%), mp 218–220 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3390, 3348 (2NH), 3051 (CH, aromatic), 2920, 2851 (CH-aliphatic), 1597 (C=C); $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 3.19–3.26 (dd, $^2J = 10.20$, $^3J = 16.60$ Hz, 1H, pyrazoline-H4), 3.72–3.79 (dd, $^2J = 11.16$, $^3J = 16.60$ Hz, 1H, pyrazoline-H4), 5.38 (t, $^3J = 7.84$, $^4J = 2.16$ Hz, 1H, pyrazoline-H5), 7.14 (t, $^3J = 7.52$ Hz, 1H, Ar-H), 7.20 (t, $^3J = 7.36$ Hz, 1H, Ar-H), 7.29–7.37 (m, 4H, Ar-H), 7.44 (d, $^3J = 7.84$ Hz, 1H, Ar-H), 7.54 (t, $^3J = 7.84$ Hz, 2H, Ar-H), 7.60 (d, $^3J = 7.72$ Hz, 1H, Ar-H), 7.68 (d, $^3J = 8.04$ Hz, 1H, Ar-H), 7.72 (d, $^3J = 7.44$ Hz, 1H, Ar-H), 7.94 (d, $^3J = 8.00$ Hz, 2H, Ar-H), 8.14 (s, 1H, Ar-H), 8.68 (s, 1H, pyrazole-H), 12.75 (s, 1H, NH, exchangeable with D $_2$ O) ppm. $^{13}\text{C NMR}$ (100 MHz; DMSO- d_6) δ_{C} 55.67 (pyrazoline-C4), 56.56 (pyrazoline-C5), 104.78, 111.72, 118.94, 119.24, 119.78, 121.84, 122.84, 123.81, 124.06, 125.30, 127.27, 127.82, 128.70, 130.14, 139.59, 141.85, 147.37, 149.95, 154.53 (Ar-C) ppm; MS, m/z (%): 464 [M^+] (33.47), analysis for C $_{27}$ H $_{20}$ N $_6$ O (444.50), calcd% C, 72.96; H, 4.54; N, 18.91 found: % C, 73.05; H, 4.68; N, 18.97.

2.1.4. General procedure for the synthesis of the target compounds 1-(5-(3-(benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3-substituted-4,5-dihydropyrazol-1-yl)ethanone 4a-d. A mixture of chalcones **2a-d** (0.002 mol) and hydrazine hydrate (0.2 mL, 98%) in glacial acetic acid (15 mL) was refluxed for 3 h. The precipitate formed during heating was filtered, dried and recrystallized from acetic acid to give the target compounds **4a-d**, respectively.

2.1.4.1. 1-(5-(3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3-phenyl-4,5-dihydropyrazol-1-yl)ethanone (4a). Yield (75%), mp 171–173 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3097, 3062 (CH, aromatic), 2928, 2851 (CH-aliphatic), 1659 (C=O), 1597 (C=C); $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 2.36 (s, 3H, CH $_3$), 3.21–3.29 (m, 1H, pyrazoline-H4), 4.01–4.10 (dd, $^2J = 11.84$, $^3J = 17.88$ Hz, 1H, pyrazoline-H4), 5.95–5.99 (dd, $^2J = 5.24$, $^3J = 11.88$ Hz, 1H, pyrazoline-H5), 7.29–7.38 (m, 4H, Ar-H), 7.46–7.48 (m, 3H, Ar-H), 7.52 (t, $^3J = 7.94$ Hz, 2H, Ar-H), 7.60 (d, $^3J = 8.00$ Hz, 1H, Ar-H), 7.71 (d, $^3J = 7.04$ Hz, 1H, Ar-H), 7.80–7.83 (m, 2H, Ar-H), 7.92 (d, $^3J = 7.88$ Hz, 2H, Ar-H), 8.47 (s, 1H, pyrazole-H) ppm. $^{13}\text{C NMR}$ (100 MHz; DMSO- d_6) δ_{C} 22.35 (CH $_3$), 42.23 (pyrazoline-C-4), 52.37 (pyrazoline-C5), 104.59, 111.70, 118.91, 121.82, 123.81, 124.21, 125.22, 127.12, 127.23, 127.42, 128.68, 129.22, 130.03, 130.76, 131.65, 139.49, 140.88, 149.94, 154.53, 154.80, 168.38 (CO) ppm; MS, m/z (%): 446 [M^+] (30.06), analysis for C $_{28}$ H $_{22}$ N $_4$ O $_2$ (446.51), calcd% C, 75.32; H, 4.97; N, 12.55 found: % C, 75.47; H, 5.06; N, 12.58.

2.1.4.2. 1-(5-(3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3-(4-methoxyphenyl)-4,5-dihydropyrazol-1-yl)ethanone (4b). Yield (75%), mp 214–215 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3048 (CH, aromatic), 2928, 2835 (CH-aliphatic), 1651 (C=O), 1609 (C=C); $^1\text{H NMR}$ (400 MHz; DMSO- d_6) δ_{H} 2.35 (s, 3H, CH $_3$), 3.22–3.30 (m, 1H, pyrazoline-H4), 3.80 (s, 3H, OCH $_3$), 3.98–4.06 (dd, $^2J = 11.84$, $^3J = 17.80$ Hz, 1H, pyrazoline-H4), 5.92–5.96 (dd, $^2J = 5.08$, $^3J = 11.76$ Hz, 1H, pyrazoline-H5), 7.00 (d, $^3J = 8.80$ Hz, 2H, Ar-H), 7.29–7.38 (m, 4H, Ar-H), 7.52 (t, $^3J = 7.88$ Hz, 2H, Ar-H), 7.62 (d, $^3J = 7.96$ Hz, 1H, Ar-H), 7.71–7.77 (m, 3H, Ar-H), 7.92 (d, $^3J = 7.92$ Hz, 2H, Ar-H), 8.44 (s, 1H, pyrazole-H) ppm; $^{13}\text{C NMR}$ (100 MHz; DMSO- d_6) δ_{C} 22.34 (CH $_3$), 42.33 (pyrazoline-C-4), 52.24



(pyrazoline-C-5), 55.79 (OCH₃), 104.57, 111.72, 114.63, 118.90, 121.81, 123.80, 124.18, 124.33, 125.22, 127.19, 127.31, 128.70, 128.81, 130.02, 139.51, 140.86, 149.96, 154.53, 161.34, 168.08, 168.63, 172.58 (CO) ppm; MS, *m/z* (%): 476 [M⁺] (28.72), analysis for C₂₉H₂₄N₄O₃ (476.54), calcd% C, 73.09; H, 5.08; N, 11.76 found: % C, 73.15; H, 5.12; N, 11.82.

2.1.4.3. *1-(5-(3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3-(3,4-dimethoxyphenyl)-4,5-dihydropyrazol-1-yl)ethanone (4c)*. Yield (75%), mp 217–218 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3097, 3050 (CH, aromatic), 2932, 2835 (CH-aliphatic), 1659 (C=O), 1601 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 2.36 (s, 3H, CH₃), 3.01–3.25 (m, 1H, pyrazoline-H4), 3.80 (s, 3H, OCH₃), 3.81 (s, 3H, OCH₃), 3.97–4.05 (dd, ²*J* = 11.72, ³*J* = 17.64 Hz, 1H, pyrazoline-H4), 5.94–5.98 (dd, ²*J* = 4.76, ³*J* = 11.68 Hz, 1H, pyrazoline-H5), 6.99 (d, ³*J* = 8.40 Hz, 1H, Ar-H), 7.31–7.38 (m, 6H, Ar-H), 7.52 (t, ³*J* = 7.74 Hz, 2H, Ar-H), 7.64 (d, ³*J* = 8.00 Hz, 1H, Ar-H), 7.71 (d, ³*J* = 7.40 Hz, 1H, Ar-H), 7.92 (d, ³*J* = 8.00 Hz, 2H, Ar-H), 8.43 (s, 1H, pyrazole-H) ppm; ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 21.51 (CH₃), 42.32 (pyrazoline-C4), 52.29 (pyrazoline-C5), 56.01 (OCH₃), 56.04 (OCH₃), 104.57, 109.62, 111.75, 111.87, 118.89, 120.98, 121.79, 123.80, 124.30, 124.42, 125.21, 127.17, 127.23, 128.72, 130.00, 139.53, 140.83, 149.20, 150.00, 151.23, 154.54, 154.65, 168.01 (Ar-C), 172.53 (CO) ppm; MS, *m/z* (%): 506 [M⁺] (28.64), analysis for C₃₀H₂₆N₄O₄ (506.56), calcd% C, 71.13; H, 5.17; N, 11.06 found: % C, 71.26; H, 5.20; N, 10.94.

2.1.4.4. *1-(5-(3-(Benzofuran-2-yl)-1-phenyl-1H-pyrazol-4-yl)-3-(1H-benzof[d]imidazol-2-yl)-4,5-dihydropyrazol-1-yl)ethanone (4d)*. Yield (75%), mp 130–132 °C, IR ($\nu_{\max}/\text{cm}^{-1}$): 3394 (NH), 3062 (CH, aromatic), 2924, 2851 (CH-aliphatic), 1655 (C=O), 1597 (C=C); ¹HNMR (400 MHz; DMSO-*d*₆) δ_{H} 2.43 (s, 3H, CH₃), 2.73–2.79 (dd, ²*J* = 8.00, ³*J* = 15.32 Hz, 1H, pyrazoline-H4), 2.86–2.96 (dd, ²*J* = 8.20, ³*J* = 14.52 Hz, 1H, pyrazoline-H4), 4.14–4.22 (dd, ²*J* = 12.16, ³*J* = 18.12 Hz, 1H, pyrazoline-H5), 6.98 (m, 2H, Ar-H), 7.15–7.41 (m, 2H, Ar-H), 7.46–7.58 (m, 6H, Ar-H), 7.65–7.74 (m, 4H, Ar-H), 8.25 (s, 1H, pyrazole-H), 12.20 (br.s, 1H, NH, D₂O exchangeable) ppm; ¹³C NMR (100 MHz; DMSO-*d*₆) δ_{C} 18.65 (CH₃), 42.20 (pyrazoline-C4), 52.10 (pyrazoline-C5), 104.48, 105.04, 111.64, 114.73, 118.64, 118.79, 121.74, 121.77, 123.69, 125.24, 126.96, 128.76, 128.82, 130.05, 130.12, 139.55, 143.58, 149.74, 152.80, 154.23 (Ar-C), 168.10 (CO) ppm; MS, *m/z* (%): 486 [M⁺] (30.03), analysis for C₂₉H₂₂N₆O₂ (486.54), calcd% C, 71.59; H, 4.56; N, 17.27 found: % C, 71.62; H, 4.72; N, 17.30.

2.2. Biological assessment

2.2.1. *In vitro* anticancer activity against 60 cell lines

2.2.1.1. *Preliminary screening at single high dose (10 μM)*. All the synthesized compounds **2a–d**, **3a–d** and **4a–d**, were selected by the National Cancer Institute (NCI), USA, for a single-dose screening assay against a panel of sixty human cell lines.^{15,39–41} The experimental procedure and resulting data are presented in the SI.

2.2.1.2. *Five-dose full NCI 60 cell panel assay*. The compound **3d** was further evaluated by the National Cancer Institute (NCI), USA, using a five-dose screening assay (0.01, 0.1, 1, 10, and 100 μM) against a panel of sixty human cell lines.^{15,39–41} The experimental methods and corresponding results are detailed in the SI.

The cytotoxicity assays were done at the National Cancer Institute (NCI), Bethesda, USA against 60 cell lines according to the protocol of the Drug Evaluation Branch, NCI.^{15,39–41}

2.2.2. *In vitro* multikinase inhibition assessment.

Compound **3d**, which exhibited the most potent anti-proliferative activity, was further examined for its inhibitory activities against the c-MET, B-Raf, Pim-1, EGFR, and VEGFR-2 kinases. More details are presented in the SI.

2.2.3. Cell cycle analysis. The MCF-7 cell line was treated with the most potent compound **3d** at its GI₅₀ concentration for 48 h. More details are presented in the SI.

2.2.4. Apoptosis assay. The annexin V-FITC apoptosis detection kit (BD Biosciences) was used to quantify the percentage of cells undergoing apoptosis and detect the modes of cell death, either by apoptosis or necrosis, in the presence or absence of the active compound **3d**. The experiment was carried out according to the manufacturer's protocol. More details are presented in the SI.


2.3. *In silico* study

AutoDock Vina 1.1.2 (ref. 69 and 70) was employed to perform the docking studies, using the human cMET protein structure (PDB 6SDE), EGFR (PDB 1XKK), VEGFR2 (PDB 4ASD), mutated B-Raf "V600E" (PDB 4XV2) and Pim-1 (PDB 1YHS) to evaluate the binding potential of the newly synthesized compound **3d** in comparison to the reference drug for each enzyme. MGL Tools 1.5.7 was used to prepare and convert the protein and ligand files to pdbqt format. The results were visualized with Discovery Studio Visualizer v21.1.0.20298.

3. Results and discussion

3.1. Chemistry

The synthetic methods used in this investigation to create the novel derivatives of the benzofuran-pyrazole hybrid are shown



Scheme 1 Synthesis of the target pyrazoline derivatives.



Table 1 *In vitro* growth inhibition% (GI%) of the NCI 60 cancer cell line panel after treatment with 10 μ M of the benzofuran–pyrazole hybrids 2–4

| Cell name | GI% | | | | | | | | | | | |
|---------------------------------|-------|-------|-------|-------|--------|-------|-------|-------|-------|-------|-------|-------|
| | 2a | 2b | 2c | 2d | 3a | 3b | 3c | 3d | 4a | 4b | 4c | 4d |
| Leukemia | | | | | | | | | | | | |
| CCRF-CEM | — | 19.37 | 8.09 | — | 12.98 | 17.25 | 84.09 | L | 15.54 | 10.80 | 9.93 | 10.91 |
| HL-60(TB) | 7.64 | 10.93 | 6.49 | 8.55 | 0.73 | 2.83 | 88.80 | L | 2.27 | 0.51 | 12.17 | 5.44 |
| K-562 | 5.10 | 8.35 | 5.48 | 4.77 | 6.49 | 7.50 | 87.48 | 92.52 | 6.90 | 5.81 | 7.80 | 2.81 |
| MOLT-4 | 3.22 | 7.84 | 4.38 | 3.61 | 0.33 | 8.04 | 80.97 | 88.75 | 7.01 | 7.68 | 8.51 | 5.60 |
| RPMI-8226 | — | 10.27 | 4.63 | 0.67 | 2.58 | 7.55 | 88.22 | L | 6.01 | 4.36 | 11.35 | 4.74 |
| SR | 17.52 | 16.61 | 17.15 | 14.03 | 15.96 | 7.24 | 77.33 | 91.17 | 17.00 | 12.12 | 16.71 | 18.72 |
| Non-small lung carcinoma | | | | | | | | | | | | |
| A549/ATCC | 4.22 | — | — | — | 3.63 | — | 57.50 | 87.82 | — | — | 2.60 | — |
| EKVX | 0.89 | 5.88 | 0.81 | 2.15 | 6.43 | 0.52 | 57.67 | 78.25 | 6.06 | — | 2.78 | 5.61 |
| HOP-62 | — | 2.25 | 4.42 | 0.08 | 2.07 | 4.32 | 33.71 | 74.46 | 1.18 | 2.33 | 3.35 | — |
| HOP-92 | — | 18.73 | 13.94 | — | 22.19 | 3.27 | 75.25 | L | 16.24 | 8.59 | — | 8.82 |
| NCI-H226 | — | 0.47 | 1.83 | — | 8.13 | 1.48 | 68.39 | 34.35 | 0.69 | — | 1.68 | 3.03 |
| NCI-H23 | 1.16 | — | — | — | — | — | 53.25 | 78.78 | — | — | 3.23 | — |
| NCI-H322M | — | 2.02 | — | — | 1.85 | 2.93 | 41.54 | 85.31 | 2.33 | 3.11 | 2.32 | 2.19 |
| NCI-H460 | — | — | — | — | — | — | 81.94 | 97.07 | — | — | — | — |
| NCI-H522 | 3.81 | 0.40 | 1.92 | 0.40 | 3.69 | 0.82 | 51.41 | 96.77 | 2.75 | 1.65 | 1.54 | 1.70 |
| Colon cancer | | | | | | | | | | | | |
| COLO 205 | — | — | — | — | 91.61 | — | 47.04 | — | — | — | — | — |
| HCC-2998 | — | — | — | — | 66.78 | — | 64.60 | 70.76 | — | — | — | — |
| HCT-116 | — | — | 0.17 | — | 99.83 | — | 74.37 | 76.76 | — | — | — | — |
| HCT-15 | — | — | 1.66 | — | 75.31 | 1.12 | 49.94 | 83.02 | 2.61 | 0.50 | 2.45 | 1.38 |
| HT29 | — | — | — | — | 54.87 | — | 64.31 | 64.97 | 0.65 | — | — | 0.62 |
| KM12 | 1.62 | — | — | — | 62.60 | — | 68.12 | 91.86 | — | — | 1.20 | — |
| SW-620 | 0.70 | — | — | — | 79.60 | — | 47.04 | 76.92 | — | — | 4.67 | — |
| CNS cancer | | | | | | | | | | | | |
| SF-268 | 4.98 | — | 1.66 | — | — | — | 61.15 | 72.21 | — | — | 4.67 | 1.38 |
| SF-295 | 5.84 | 7.09 | 9.48 | 4.39 | 9.51 | 1.43 | 58.47 | 84.73 | 5.69 | — | 4.33 | 9.71 |
| SF-539 | 0.23 | 3.20 | 4.21 | 1.65 | 6.00 | 4.09 | 56.77 | 85.47 | 8.41 | 2.46 | 1.95 | 0.68 |
| SNB-19 | 4.72 | 6.26 | 4.96 | 4.33 | 5.98 | 2.46 | 59.83 | 92.86 | 5.00 | 2.45 | 6.15 | 4.75 |
| SNB-75 | 19.77 | — | — | 20.70 | −10.52 | 0.28 | 58.00 | 65.51 | 1.45 | — | 14.70 | — |
| U251 | — | — | — | — | 2.33 | — | 60.18 | 85.69 | 1.60 | — | — | — |
| Melanoma | | | | | | | | | | | | |
| LOX IMVIL | — | 4.44 | — | — | — | — | 65.24 | 75.62 | 4.25 | 2.30 | 3.27 | — |
| MALME-3M | 1.12 | 1.29 | 5.86 | 0.07 | 3.67 | 4.88 | 30.46 | 81.85 | 1.02 | 0.92 | 3.54 | 5.76 |
| M14 | 0.52 | — | 1.79 | — | 0.57 | 4.94 | 63.24 | 83.05 | — | — | — | 2.74 |
| MDA-MB-435 | 0.51 | — | — | — | −6.37 | — | 65.91 | 83.49 | — | — | — | — |
| SK-MEL-2 | — | — | — | — | −6.14 | — | 47.50 | 99.44 | — | — | 1.30 | — |
| SK-MEL-28 | — | — | — | — | 2.00 | — | 35.60 | 80.99 | — | — | — | 1.16 |
| SK-MEL-5 | — | — | 1.65 | — | 0.18 | — | 74.73 | 90.42 | 0.15 | — | 5.22 | 0.87 |
| UACC-257 | 5.50 | — | — | 1.66 | 6.06 | — | 45.64 | 79.15 | — | — | 6.12 | 1.22 |
| UACC-62 | 2.28 | 7.77 | 4.68 | — | 7.34 | 8.16 | 62.47 | L | 8.33 | 5.56 | — | 2.82 |
| Ovarian carcinoma | | | | | | | | | | | | |
| IGROV1 | — | — | — | — | — | — | 61.79 | 89.61 | — | — | — | — |
| OVCAR-3 | — | — | — | — | — | — | 65.22 | 81.63 | — | — | — | — |
| OVCAR-4 | 1.64 | — | — | — | — | — | 58.72 | 66.52 | — | — | — | — |
| OVCAR-5 | 0.37 | 2.97 | 0.00 | — | 3.74 | — | 41.14 | 66.23 | 3.55 | — | 5.34 | 6.06 |
| OVCAR-8 | — | — | — | — | — | 1.00 | 63.70 | 86.94 | — | — | — | — |
| NCI/ADR-RES | — | — | 1.79 | — | — | — | — | — | — | — | — | — |
| SK-OV-3 | — | 4.75 | 11.15 | 4.37 | 8.93 | 6.45 | 32.78 | 62.21 | 9.60 | 4.82 | 7.21 | — |
| Renal carcinoma | | | | | | | | | | | | |
| 4.42786-0 | 1.14 | 1.04 | 2.44 | 0.74 | — | — | 52.36 | 71.73 | 2.59 | — | 4.42 | 4.06 |
| A498 | 1.16 | — | 6.80 | — | 6.22 | 2.47 | 7.63 | 54.33 | — | — | 3.05 | 5.12 |
| ACHN | — | 0.20 | 0.70 | — | — | 5.79 | 74.84 | 92.45 | — | — | — | — |
| CAKI-1 | 15.01 | 12.51 | 10.30 | 10.24 | 11.52 | 17.83 | 76.85 | 92.45 | 13.36 | 13.20 | 13.64 | 7.51 |



Table 1 (Contd.)

| Cell name | GI% | | | | | | | | | | | |
|---------------------------|------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| | 2a | 2b | 2c | 2d | 3a | 3b | 3c | 3d | 4a | 4b | 4c | 4d |
| RXF 393 | — | — | — | — | — | — | 36.89 | 63.52 | — | — | — | 2.67 |
| SN12C | 0.82 | — | 10.90 | 3.48 | 12.27 | — | 63.01 | 88.17 | — | — | 10.86 | 6.54 |
| TK-10 | 5.20 | 6.22 | 6.22 | 3.41 | 10.65 | 3.17 | 42.27 | 75.14 | 11.62 | 7.73 | — | 15.06 |
| UO-31 | 7.39 | 14.83 | 15.32 | 7.86 | 14.55 | 26.14 | 80.36 | L | 15.50 | 17.79 | 11.00 | 13.92 |
| Prostate carcinoma | | | | | | | | | | | | |
| PC-3 | — | 4.83 | 7.06 | — | 8.08 | 12.08 | 66.98 | 91.14 | 8.29 | 6.35 | 3.89 | 5.99 |
| DU-145 | — | — | — | — | — | — | 58.05 | 67.57 | — | — | 1.59 | — |
| Breast carcinoma | | | | | | | | | | | | |
| -MCF7 | 5.38 | 0.75 | 9.78 | 5.90 | 7.06 | 2.03 | 77.82 | 85.98 | 11.19 | 9.85 | 8.83 | 5.40 |
| BT-549 | — | 69.00 | 16.27 | 15.03 | 0.80 | 4.37 | — | — | 9.06 | — | 3.97 | 9.21 |
| T-47D | — | 83.54 | 9.23 | 7.67 | 10.71 | 2.60 | 81.51 | 88.48 | 12.41 | 2.42 | 5.68 | 18.84 |
| MDA-MB-468 | 0.19 | 65.44 | 0.93 | 1.87 | — | 7.03 | 78.06 | 70.95 | 3.32 | 2.43 | 8.49 | — |
| Mean GI% | 0.37 | 0.61 | 2.16 | −0.94 | 2.24 | 0.8 | 60.71 | 83.58 | 1.66 | −2.13 | 2.51 | 1.26 |

in Scheme 1. The crucial starting material 3-(benzofuran-2-yl)-1-phenyl-1*H*-pyrazole-4-carbaldehyde (**1**) was produced using the published Vilsmeier–Haack process.⁷¹ Briefly, to a cooled solution of phosphorus oxychloride in anhydrous DMF at 0 °C, the pyrazole precursor was added portion-wise under stirring. The reaction mixture was then allowed to warm to room temperature and stirred for 4–6 h. After completion, the mixture was poured onto crushed ice, neutralized with saturated sodium acetate solution, and stirred for 30 min. The resulting precipitate was filtered, washed with water, and recrystallized from ethanol to afford the target aldehyde **1** in 70–80% yield. The structure was confirmed by comparison with literature data. Chalcones have a history of being used as useful bridges in the synthesis of five- and six-membered heterocycles.⁷² Thus, the developed synthetic approach was designed to construct benzofuran–pyrazole-based dihydropyrazole derivatives efficiently and under relatively mild conditions. The cyclocondensation of chalcones **2a–d** with hydrazine hydrate was performed in two solvent systems, absolute ethanol and glacial acetic acid, to direct the formation of two distinct series of products. Refluxing in absolute ethanol favored the formation of the 3-substituted dihydropyrazolyl pyrazole derivatives **3a–d**. Ethanol was chosen because it dissolves both hydrazine and chalcones well, providing a homogeneous reaction medium that promotes smooth cyclization without significant byproduct formation. Its protic nature may also stabilize reaction intermediates *via* hydrogen bonding, supporting the selective formation of the pyrazoline ring. Conversely, cyclocondensation in glacial acetic acid led to the formation of the 1-substituted dihydropyrazolyl ethanone derivatives **4a–d**. Acetic acid served both as a solvent and mild acid catalyst, activating the chalcone carbonyl group and directing regioselective ring closure. The acidic environment stabilizes protonated intermediates, favoring the observed selectivity toward the 1-substituted products. In comparison to alternative methods reported in the literature, the adopted conditions offered distinct advantages.

For instance, cyclization under microwave irradiation achieves fast conversion but may risk partial decomposition of the labile groups or generate side products, requiring further purification.⁷³ Similarly, cyclization in the presence of strong mineral acids (*e.g.*, concentrated HCl and H₂SO₄) can complicate isolation by promoting polymerization or overreaction.⁷⁴ In contrast, our classical reflux protocol requires no specialized equipment, proceeds under atmospheric pressure, and provides high yields (around 75%) with simple filtration and recrystallization, highlighting its operational simplicity and selectivity.

The molecular structures of the synthesized derivatives were validated by elemental tests and spectral data. A pair of doublets at δ 6.31–7.10 and 7.60–8.10 ppm was visible in the ¹H NMR spectra of the derived derivatives **2a–d**. These doublets were caused by the *trans*-olefinic protons and had coupling constant values of $J = 15.0$ – 15.5 Hz. Besides the expected signals of the parent protons, the ¹H NMR spectra of compounds **3a–d** and **4a–d** exhibited the two methylene protons of CH₂ of the pyrazoline ring as a pair of doublets in the range of δ 2.91–3.11 and 3.41–3.65 ppm, while its methine proton CH presented as two doublets at the range of δ 5.19–5.26 ppm.

3.2. Biological assessment

3.2.1. *In vitro* preliminary antitumor effects at a single dose (10 μ M) against the full NCI 60 cell panel. The newly developed benzofuran–pyrazole derivatives **2–4** underwent preliminary anticancer screening at the National Cancer Institute (NCI), USA, as part of the screening project.

Following the NCI, USA protocol (<https://dtp.nci.nih.gov>), all the recently created compounds were assessed *in vitro* using a single dose (10 μ M) against full NCI 60 cell line panels that implied nine distinct categories of cancer, including leukemia, non-small cell lung cancer, melanoma, CNS cancer, ovarian cancer, renal cancer, prostate cancer, and breast cancer.

The results are listed as percentage of growth inhibition (GI%) of the evaluated derivatives against the full panel of cell



Table 2 Anti-proliferative activity of compound **3d** on NCI cancer cell lines at 5 dose levels

| Leukemia | GI ₅₀ (μM) | Colon cancer | GI ₅₀ (μM) | Melanoma | GI ₅₀ (μM) | Renal cancer | GI ₅₀ (μM) |
|----------------------------|-----------------------|--------------|-----------------------|----------------|-----------------------|-----------------|-----------------------|
| CCRF-CEM | 3.11 | COLO 205 | 5.28 | LOX IMVI | 3.71 | 786-0 | 4.31 |
| HL-60(TB) | 2.56 | HCC-2998 | 5.25 | MALME-3M | 6.19 | A498 | 12.70 |
| K-562 | 3.37 | HCT-116 | 5.46 | M14 | 3.22 | ACHN | 3.11 |
| MOLT-4 | 4.13 | HCT-15 | 3.18 | MDA-MB-435 | 4.24 | CAKI-1 | 2.57 |
| RPMI-8226 | 3.04 | HT29 | 6.46 | SK-MEL-2 | 2.53 | RXF 393 | 6.25 |
| SR | 3.15 | KM12 | 5.55 | SK-MEL-28 | 4.58 | SN12C | 3.42 |
| Non-small cell lung cancer | | SW-620 | 5.95 | SK-MEL-5 | 2.76 | TK-10 | 4.97 |
| A549/ATCC | 3.86 | CNS cancer | | UACC-257 | 6.24 | UO-31 | 2.10 |
| EKVX | 2.69 | SF-268 | 4.51 | UACC-62 | 1.84 | Prostate cancer | |
| HOP-62 | 3.66 | SF-295 | 2.59 | Ovarian cancer | | PC-3 | 3.47 |
| HOP-92 | 4.78 | SF-539 | 3.97 | IGROV1 | 3.34 | DU-145 | 5.15 |
| NCI-H226 | 6.62 | SNB-19 | 3.77 | OVCAR-3 | 4.91 | Breast cancer | |
| NCI-H23 | 3.69 | SNB-75 | 2.72 | OVCAR-4 | 3.51 | MCF7 | 2.75 |
| NCI-H322M | 3.77 | U251 | 3.72 | OVCAR-5 | 5.52 | MDA-MB-231/ATCC | 4.78 |
| NCI-H460 | 3.64 | | | OVCAR-8 | 5.88 | HS 578T | 7.94 |
| NCI-H522 | 3.48 | | | NCI/ADR-RES | 3.16 | BT-549 | 3.85 |
| | | | | | | T-47D | 3.12 |

lines, ranging from 0 to 100% (Table 1). The COMPARE tool was used to analyze the single-dose evaluation findings of all the evaluated derivatives **2–4** against the sixty cancer cell lines.

Except for **3c** and **3d**, which showed superior activity, the GI values of the examined compounds showed moderate to weak anticancer activity. Compounds **3c** and **3d** demonstrated promising broad-spectrum cytotoxic activity against several of the tested cancer cell lines.

According to the obtained data (Table 1), compound **3d** exhibited a pronounced selective GI% against 2 subpanels of leukemia cancer cell lines, namely, K-562 and SR (GI% = 92.52%, and 91.17%, respectively); 2 subpanels of non-small cell lung carcinoma (NSCLC), NCI-H460 and NCI-H522 (GI% = 97.07% and 96.77%); KM12 subpanel of colon cancer (GI% = 91.86%); SNB-19 subpanel of CNS cancer (GI% = 92.86%); 2 subpanels of melanoma cancer cell lines, SK-MEL-2 and SK-MEL-5 (GI% = 99.44% and 90.42%); and 2 subpanels of renal carcinoma lines, ACHN and CAKI-1 (GI% = 92.45% and 92.45%), respectively.

The obtained results demonstrated the influence of the type of attached ring system to the linker bridge on the anticancer

activity. The presence of the 1*H*-benzo[*d*]imidazol-2-yl ring in **3d** produced the most potent anticancer activity against various subpanels of examined cancer cell lines, which is expected due to the extra hydrophobic interactions with different proteins, resulting in a better fit in the active sites of the enzymes **3d** acts on. Additionally, the unsubstituted NH group of the attached pyrazoline ring acts as a centre for hydrogen-bonding interactions.

The benzofuran-pyrazole-benzo[*d*]imidazole derivative **3d** was selected for further detailed study at five different concentrations due to its significant data in the single-dose study.

3.2.2. In vitro anticancer assessment at 5 doses on full NCI 60 cell panel. In the second step, the chosen candidate **3d** (D-804233/1), which met established threshold inhibition standards, was tested against all 60 cell lines at tenfold dilutions of five distinct concentrations (0.01, 0.1, 1, 10, and 100 μM).^{75,76}

Table 2 displays the calculated response parameters, GI₅₀ and LC₅₀, against the assessed cell lines. GI₅₀ denotes the compound concentration that results in a 50% suppression in net cell growth, and LC₅₀ for the lethal dose, which denotes the compound concentration that results in 50% loss of the initial cells.⁷⁷ Additionally, the subpanel and full panel mean graph midpoints (MG-MID) were computed for the GI₅₀ values to represent the average activity parameter over the subpanels and full panel cell lines for **3d** (Table 3). The five-dose anticancer screening showed that **3d** had significant effects on the examined cancer cell lines (39 of them had GI₅₀ values less than 4.00 μM, and the values ranged from 1.84 to 6.62 μM). Luckily, the LC₅₀ values of **3d** exceeded 100 μM against the majority of examined cell lines with a few exceptions, indicating that it had non-lethal effects (Table 3).

The selectivity index (SI) was computed by dividing the full panel MG-MID (μM) for the tested compound by its subpanel MG-MID (μM). SI is a measuring factor for compound selectivity towards subpanels. Compound **3d** showed non-selective, broad-spectrum anticancer activity against all the cancer subpanels, with selectivity ratios ranging from 0.83 to 1.3 (Table 3).


Table 3 Mean graph midpoint values (MG-MIDa) for the subpanel tumor cell line GI₅₀ parameter (μM)^a

| Subpanel type | MG-MID | Selectivity index |
|-----------------|--------|-------------------|
| Leukemia | 3.23 | 1.30 |
| NSCL cancer | 4.02 | 1.04 |
| Colon cancer | 5.02 | 0.83 |
| CNS cancer | 3.55 | 1.18 |
| Melanoma | 3.92 | 1.07 |
| Ovarian cancer | 4.32 | 0.97 |
| Renal cancer | 4.93 | 0.85 |
| Prostate cancer | 4.31 | 0.97 |
| Breast cancer | 4.49 | 0.935 |

^a Full panel MG-MID for **3d** = 4.20 μM.

Table 4 Multi-targeting suppression of compound **3d** against different protein kinases measured in $\mu\text{g mL}^{-1}$

| Compound name | B-Raf (V600E) | c-Met | Pim-1 | EGFR (WT) | VEGFR-2 |
|---------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| 3d | 0.078 ± 0.004 | 0.405 ± 0.017 | 1.053 ± 0.046 | 0.177 ± 0.007 | 0.275 ± 0.011 |
| Vemurafenib | 0.027 ± 0.001 | | | | |
| Erlotinib | | | | 0.220 ± 0.15 | |
| Staurosporine | | 0.40 ± 0.014 | 0.213 ± 0.009 | | |
| Sorafenib | | | | | 1.12 ± 0.10 |

Fig. 3 Cell cycle detection of compound **3d** on the HepG-2 cancer cell line in comparison with the untreated cells.

3.2.3. *In vitro* multikinase inhibition assessment. Based on the obtained anticancer evaluation, the most potent compound, **3d**, was further assessed for its *in vitro* multi-targeting PK-inhibiting impact against B-Raf (V600E), c-Met, Pim-1, EGFR (WT), and VEGFR-2. The most common PKI drugs, vemurafenib, erlotinib, staurosporine, and sorafenib, cause intracellular phosphorylation-inhibiting effects against the examined protein kinases, serving as positive controls^{78,79} (Table 4). Compound **3d** was 1.2- and 4.1-times more effective at suppressing EGFR (WT) and VEGFR-2 ($\text{IC}_{50} = 0.177 \pm 0.007$ and $0.275 \pm 0.011 \mu\text{g mL}^{-1}$) than the reference drugs erlotinib and sorafenib ($\text{IC}_{50} = 0.220 \pm 0.15$ and $1.12 \pm 0.10 \mu\text{g mL}^{-1}$), respectively. Also, it had the same effect on c-Met as staurosporine, with IC_{50} values of $0.405 \pm 0.017 \mu\text{g mL}^{-1}$.

Alternatively, the kinases B-Raf (V600E) and Pim-1 were 2.8- and 4.9-times less sensitive to the tested compound ($\text{IC}_{50} = 0.078 \pm 0.004$ and $1.053 \pm 0.046 \mu\text{g mL}^{-1}$) than the reference standards vemurafenib and staurosporine (IC_{50} values of 0.027 ± 0.001 and $0.213 \pm 0.009 \mu\text{g mL}^{-1}$), respectively. The resultant data showed a favorable correlation with the corresponding values for their antiproliferative activities.

The promising multikinase suppression activity was confirmed by a docking study, underscoring the significance of the NH group of the benzo[*d*]imidazole ring, which facilitates interactions of **3d** through hydrogen bonds with various amino acid residues, including ARG1086, GLU885, LYS483, and ASP594 of the evaluated kinases, alongside the hydrophobic, pi-cation, and pi-sulphur interactions of the other fragments of the molecule with various amino acid residues.



Table 5 Apoptosis detection assay for compound **3d** in HepG-2 cancer cells

| | Total | Early | Late | Necrosis |
|-------------|-------|-------|-------|----------|
| NH/HepG-2 | 44.05 | 24.66 | 15.07 | 4.32 |
| Cont.HepG-2 | 2.09 | 0.52 | 0.17 | 1.4 |

3.2.4. Cell cycle distribution and apoptosis detection



3.2.4.1. Cell cycle assay. Normal cell growth and division are governed by four cell cycle stages of pre-G1, G1, S, and G2/M phases. However, the majority of cancer cells frequently undergo uncontrollable cell divisions brought on by cell cycle down-regulation. Therefore, targeting particular cell cycle stages is a crucial therapeutic approach in the management of antiproliferative disorders.⁸⁰

Given that **3d** has emerged as a well-balanced active compound that functions as both an anticancer agent and a multi-targeting protein kinase suppressor, it was of interest to gain a deeper understanding of how **3d** inhibits the growth of cancer cells. A propidium iodide (PI) staining experiment was

performed in this study to look at its effect on cell cycle distribution and apoptosis activation.^{81,82}

When **3d** was added to MCF-7 cancer cells at its GI_{50} concentration of 2.75 μ M, the percentage of cells in the G0–G1 phase increased compared to cells that had not been treated (61.03% vs. 48.39%). Conversely, the cell percentage in the S phase was reduced from 27.51% in the control cells to 23.077% in the **3d**-treated cells and in the G2/M stage, from 24.1% in the control cells to 15.9% in the **3d**-treated cells. This blocked cell cycle passage at the G0–G1 stage can stop cells from dividing and growing, which is in line with that shown by other tests about the ability of compound **3d** to stop cell division and growth (Fig. 3).

3.2.4.2. Apoptosis detection. Flow cytometry assay employing annexin V-FITC and propidium iodide double labeling was used to further examine the apoptotic impact of compound **3d**.^{81,82} Exposure of HepG-2 cancer cells to **3d** for 24 h resulted in early apoptosis with a value of 24.66% in HepG-2 cells, compared to 0.52% in the untreated control cells. Additionally, **3d** enhanced the late apoptotic effect from 0.17% in the control cells to 15.07% in the treated cells. Moreover, compound **3d** promoted necrosis by 4.32% in the **3d**-treated cells in comparison with

**Fig. 4** Apoptosis detection of compound **3d** on the HepG-2 cancer cell line in comparison with the untreated cell line.**Fig. 5** Validation of the docking procedure to c-MET, EGFR, VEGFR-2, B-Raf, and Pim-1, where the co-crystallized ligand is shown in cyan and the re-docked ligand in purple.




Fig. 6 Docking poses of (A) compound **3d** and (B) staurosporine inside the active site of c-MET kinase.




Fig. 7 Docking poses of (A) compound **3d** and (B) lapatinib inside the active site of EGFR.

1.4% in the untreated ones (Table 5 and Fig. 4). These findings support the cytotoxic action of compound **3d** on HepG-2 cells. In addition, it implies that its cytotoxic impact is not only due to it initiating programmed cell death pathways in an orderly manner but also its ability to effectively complete the apoptotic process, which results in the fragmentation and removal of cancer cells.

It has been reported that suppression activity against VEGFR-2 and EGFR results in the induction of cell death *via* both the apoptosis and necrosis pathways,⁸² which explains the necrotic effect of **3d** against the examined cancer cells.

3.3. *In silico* investigation

3.3.1. Molecular docking of compound 3d. Firstly, we carried out a validation step to confirm the suitability of the

docking protocol against the five target enzymes using AutoDock Vina 1.1.2.^{69,70} We calculated the root mean square deviation (RMSD) and found it within the accepted range of 1.08 for c-MET, 1.24 for EGFR, 1.01 for VEGFR-2, 0.34 for B-Raf, and 0.23 for Pim-1 (ref. 83) (Fig. 5).

The tested compound **3d** showed comparable activity to that of staurosporine against c-MET kinase with IC_{50} values of 0.405 ± 0.017 and $0.40 \pm 0.014 \mu\text{g mL}^{-1}$, respectively, and the docking study proved this finding given that it has a docking binding energy score of $-9.0 \text{ kcal mol}^{-1}$ compared to that of the staurosporine $-10.6 \text{ kcal mol}^{-1}$. Compound **3d** binds to ARG1086 through hydrogen bonding in addition to pi-cation interactions with ARG1166, LYS1110 and pi-anion forces to ASP1231 (Fig. 6).

The binding affinity of **3d** was tested against EGFR in comparison to the co-crystallized ligand lapatinib. It has good affinity for the EGFR active site in comparison to lapatinib with






Fig. 8 Docking poses of (A) compound **3d** and (B) sorafenib inside the active site of VEGFR-2.




Fig. 9 Docking poses of (A) compound **3d** and (B) vemurafenib inside the active site of B-Raf "V600E".

binding energy scores of -9.2 and -11.4 kcal mol $^{-1}$, respectively. It also binds to the key amino acid MET793 through hydrophobic interactions, while lapatinib binds to it *via* hydrogen bonding (Fig. 7).

In the case of VEGFR-2, compound **3d** has a comparable binding mode to that of the co-crystallized ligand, sorafenib (Fig. 8). **3d** has an energy score of -10.1 kcal mol $^{-1}$, while that of sorafenib is -10.2 kcal mol $^{-1}$. Fig. 8 shows that both compounds bind to the key amino acid GLU885 through hydrogen bonding and LYS868 through pi-cation interactions.

Moreover, **3d** exhibits good binding affinity to the mutated B-Raf "V600E" with a score of -9.6 kcal mol $^{-1}$ compared to the reference drug vemurafenib with a value of -10.5 kcal mol $^{-1}$. It has a similar binding mode to that of vemurafenib through hydrogen bonding with LYS483 and ASP594 in addition to pi-sulfur interactions with CYS532 and PHE595, which endows it with good activity against the mutated B-Raf "V600E", as shown in Fig. 9.

Finally, the docking of **3d** against Pim-1 did not show any hydrogen bonding achieved by the reference staurosporine, instead, it binds to the ASN172 and ASP186 residues (Fig. 10).






Fig. 10 Docking poses of (A) compound **3d** and (B) staurosporine inside the active site of Pim-1.




Fig. 11 Bioavailability radar chart of compound **3d** (the pink area represents the accepted range for each of the studied parameters).

In analyzing the binding interactions of compound **3d** across various kinase targets, it is crucial to consider both the conserved and divergent structural features within the ATP-binding pocket and allosteric sites of these kinases. Despite sharing a common ATP-binding region, kinases such as B-Raf (V600E), c-Met, Pim-1, EGFR, and VEGFR-2 exhibit distinct structural nuances that govern the binding affinity and selectivity. For instance, B-Raf (V600E) harbors a mutated valine-to-glutamic acid residue at position 600, resulting in a hydrophobic pocket alteration that accommodates inhibitors such as vemurafenib more effectively.⁸⁴ In contrast, Pim-1 features a less hydrophobic allosteric pocket, explaining the reduced binding efficacy of **3d**, as observed in our study.⁸⁵

Similarly, the EGFR and VEGFR-2 kinases share a relatively conserved hinge region that facilitates hydrogen bonding interactions, as evidenced by the binding of **3d** to MET793 in EGFR and GLU885 in VEGFR-2. However, subtle variations in the surrounding residues, such as the bulky LYS868 in VEGFR-

2, allow differential interactions, contributing to the distinct binding profiles observed.^{86,87} c-Met, characterized by a more polar active site due to residues such as ARG1086 and ASP1231, presents a mixed hydrophobic-polar environment that enables pi-cation and pi-anion interactions, respectively, with the tested compound.⁸⁸

Thus, the observed multi-kinase inhibition profile of **3d** can be rationalized by its structural adaptability to accommodate diverse kinase pockets, facilitated by its benzofuran-pyrazole scaffold and strategically positioned aromatic and hydrogen-bond donor/acceptor functionalities. This structural versatility underscores the potential of **3d** as a multi-target kinase inhibitor capable of modulating different signalling pathways through differential binding modes. Further optimization to enhance the selectivity and minimize off-target interactions can be considered in future studies to further refine its kinase-targeting profile.

3.3.2. ADME study of compound 3d. The ADME study of compound **3d** was carried out using the free SwissADME server.⁸⁹ The bioavailability radar represents six key parameters relevant to drug-likeness (Fig. 11). **3d** has two violations represented by the points that go outside the accepted pink area, which are unsaturation because this compound has a very low fraction of sp³ carbons and insolubility.

Lipinski's rule of five⁹⁰ is also applied by measuring the molecular weight, the log *P* value, the number of hydrogen bond acceptor groups (O/N) and the number of hydrogen bond donor groups (OH/NH). Compound **3d** has no violations given that its molecular weight is 444.49 g mol⁻¹ (<500), its log value is 4.32 (<5), its number of hydrogen bond acceptor groups is 7 (<10), and its number of hydrogen bond donor groups is 2 (<5). These findings indicated the expected good oral bioavailability of **3d**.

Finally, to assess the expected GIT absorption, BBB penetration and the possibility of being a substrate for the efflux






Fig. 12 Boiled egg chart for compound **3d**.

protein permeability glycoprotein (P-gp),⁹¹ a boiled-egg chart was constructed (Fig. 12). Compound **3d** showed good human intestinal absorption (HIA), as represented by the white area in the chart, but could not penetrate the BBB, which is represented by the yellow area. Unfortunately, **3d** is expected to be a substrate for the efflux protein P-gp, which is indicated by the blue circle.

4. Conclusion

The goal of this study is to design and develop new benzofuran-pyrazole-based analogues, tethered with various substituted aromatic and heterocyclic ring systems featuring the pharmacophoric fragments of protein kinase suppressors **3a-d** and **4a-d**. The conclusions can be summarized according to the following points:

- All the new analogues were selected by the NCI to screen their antiproliferative activity against sixty human cancer cell lines (NCI60).
- The 1*H*-benzo[*d*]imidazole derivative **3d** exhibited prominent % inhibition of various cancer cell lines and advanced to the five-dose assay. Luckily, it showed remarkable antiproliferative activity against various types of cancer lines with GI₅₀ values ranging from 0.33 to 4.87 μM.
- Fortunately, its LC₅₀ exceeded 100 μM against the majority of examined cell lines, confirming its non-lethal effects.
- Due to its promising antiproliferative activity, compound **3d** was further assessed for its *in vitro* multi-targeting PK-inhibiting activity against B-Raf (V600E), c-Met, Pim-1, EGFR

(WT), and VEGFR-2. The most common PKI drugs, vemurafenib, erlotinib, staurosporine, and sorafenib, were chosen as standard controls.

- **3d** exhibited a significant suppression effect against EGFR (WT) VEGFR-2, and c-Met (IC₅₀ = 0.177 ± 0.007, 0.275 ± 0.011, and 0.405 ± 0.017, respectively). The kinases B-Raf (V600E) and Pim-1 were less sensitive to **3d** (IC₅₀ = 0.078 ± 0.004 and 1.053 ± 0.046 μg mL⁻¹) than the reference standards vemurafenib and staurosporine (IC₅₀ = 0.027 ± 0.001 and 0.213 ± 0.009 μg mL⁻¹), respectively.

- Additionally, **3d** resulted in early and late apoptosis in MCF-7 cancer cells and arrested the cell cycle at the G₀-G₁ phase.

- *In silico* molecular docking of **3d** in the active sites of the tested kinases showed good affinity and good binding interactions with amino acid residues of c-MET, EGFR, VEGFR-2, and B-Raf "V600E", with binding energy scores ranging from -9.0 to 10.5 kcal mol⁻¹.

- In addition, the ADME study exhibited that compound **3d** follows Lipinski's rule of five, indicating its expected good oral bioavailability. Also, compound **3d** has good human intestinal absorption but cannot penetrate the BBB.

- Future prospects: more studies will be carried out for further optimization of the pharmacophoric structure of the benzofuran-pyrazole-pyrazoline parent scaffold, considering the significance of the unsubstituted NH groups of the pyrazoline and the benzo[*d*]imidazole ring, which facilitate hydrogen bond interactions with various amino acid residues of the



evaluated kinases, including ARG1086, GLU885, LYS483, and ASP594, alongside the hydrophobic, pi-cation, and pi-sulphur interactions of the other fragments of the molecules with various amino acid residues. In addition, the peripheral benzimidazole has a polar imidazole ring (containing two nitrogen atoms) and a benzene ring, making it less hydrophobic overall, which directs the development of new molecules with a peripheral phenyl ring with polar and less hydrophobic substitutions, leading to more favorable docking scores and promising experimental cytotoxic and multi-kinase inhibition activity.

Also, *in vivo* and histopathological studies should be carried out in further studies to fully evaluate its safety and therapeutic efficacy. Thus, these results can provide a solid foundation for future drug discovery initiatives and contribute to the creation of new benzofuran-pyrazole-based anticancer drugs with multitargeting enzyme activities.

Conflicts of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.

Data availability

Further inquiries can be directed to the corresponding author.

The original contributions presented in the study are included in the article/SI. See DOI: <https://doi.org/10.1039/d5ra00553a>.

Acknowledgements

The authors would like to thank the National Research Centre, Cairo, Egypt.

References

- 1 P. Sharma, V. Jhawat, P. Mathur and R. Dutt, Innovation in cancer therapeutics and regulatory perspectives, *Med. Oncol.*, 2022, **39**(5), 76.
- 2 N. F. El Hamaky, A. Hamdi, W. A. Bayoumi, A. A. Elgazar and M. N. Nasr, Novel quinazolin-2-yl 1, 2, 3-triazole hybrids as promising multi-target anticancer agents: design, synthesis, and molecular docking study, *Bioorg. Chem.*, 2024, **148**, 107437.
- 3 K. Nurgali, R. T. Jagoe and R. Abalo, Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?, *Front. Pharmacol.*, 2018, **9**, 245.
- 4 M. T. Nemr, A. Elshewy, M. L. Ibrahim, A. M. El Kerdawy and P. A. Halim, Design, synthesis, antineoplastic activity of new pyrazolo [3, 4-d] pyrimidine derivatives as dual CDK2/GSK3 β kinase inhibitors; molecular docking study, and ADME prediction, *Bioorg. Chem.*, 2024, **150**, 107566.
- 5 X.-J. Liu, H.-C. Zhao, S.-J. Hou, H.-J. Zhang, L. Cheng, S. Yuan, *et al.*, Recent development of multi-target VEGFR-2 inhibitors for the cancer therapy, *Bioorg. Chem.*, 2023, **133**, 106425.
- 6 I. M. Othman, Z. M. Alamshany, N. Y. Tashkandi, M. A. Gad-Elkareem, S. S. Abd El-Karim and E. S. Nossier, Synthesis and biological evaluation of new derivatives of thieno-thiazole and dihydrothiazolo-thiazole scaffolds integrated with a pyrazoline nucleus as anticancer and multi-targeting kinase inhibitors, *RSC Adv.*, 2022, **12**(1), 561–577.
- 7 H. A. Gomaa, M. E. Shaker, S. I. Alzarea, O. Hendawy, F. A. Mohamed, A. M. Gouda, *et al.*, Optimization and SAR investigation of novel 2, 3-dihydropyrazino [1, 2-a] indole-1, 4-dione derivatives as EGFR and BRAFV600E dual inhibitors with potent antiproliferative and antioxidant activities, *Bioorg. Chem.*, 2022, **120**, 105616.
- 8 K. N. Shah, R. Bhatt, J. Rotow, J. Rohrberg, V. Olivas, V. E. Wang, *et al.*, Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer, *Nat. Med.*, 2019, **25**(1), 111–118.
- 9 K. S. Bhullar, N. O. Lagarón, E. M. McGowan, I. Parmar, A. Jha, B. P. Hubbard, *et al.*, Kinase-targeted cancer therapies: progress, challenges and future directions, *Mol. Cancer*, 2018, **17**, 1–20.
- 10 S. Ali, M. Alam and M. I. Hassan, Kinase inhibitors: an overview, *Protein Kinase Inhibitors*, 2022, pp. 1–22.
- 11 R. M. Allam, A. M. El Kerdawy, A. E. Gouda, K. A. Ahmed and H. T. Abdel-Mohsen, Benzimidazole-oxindole hybrids as multi-kinase inhibitors targeting melanoma, *Bioorg. Chem.*, 2024, **146**, 107243.
- 12 S. S. Abd El-Karim, Y. M. Syam, A. M. El Kerdawy and H. T. Abdel-Mohsen, Rational design and synthesis of novel quinazolinone N-acetohydrazides as type II multi-kinase inhibitors and potential anticancer agents, *Bioorg. Chem.*, 2024, **142**, 106920.
- 13 H. K. Abd El-Mawgoud, A. M. AboulMagd, M. T. Nemr, M. M. Hemdan, A. I. Hassaballah and P. S. Farag, Design, synthesis and cytotoxic evaluation of new thieno [2, 3-d] pyrimidine analogues as VEGFR-2/AKT dual inhibitors, apoptosis and autophagy inducers, *Bioorg. Chem.*, 2024, **150**, 107622.
- 14 A. Ghith, N. S. Ismail, K. Youssef and K. A. Abouzid, Medicinal attributes of thienopyrimidine based scaffold targeting tyrosine kinases and their potential anticancer activities, *Arch. Pharmazie*, 2017, **350**(11), 1700242.
- 15 S. A. El-Metwally, M. M. Abou-El-Regal, I. H. Eissa, A. B. Mehany, H. A. Mahdy, H. Elkady, *et al.*, Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents, *Bioorg. Chem.*, 2021, **112**, 104947.
- 16 H.-A. S. Abbas and S. S. Abd El-Karim, Design, synthesis and anticervical cancer activity of new benzofuran-pyrazol-hydrazono-thiazolidin-4-one hybrids as potential EGFR inhibitors and apoptosis inducing agents, *Bioorg. Chem.*, 2019, **89**, 103035.
- 17 S. M. Ali, A. HI Faraag, H. R. Elgiushy, T. S. El-Mahdy, A. A. Askar, A. S. Hassan, *et al.*, Synthesis, in silico and in vitro antimicrobial evaluation of cyanoketene S, N-acetals



- and their pyrazoles against staphylococcus aureus DNA gyrase enzyme, *J. Adv. Pharm. Res.*, 2021, **5**(3), 341–361.
- 18 D. Fabbro, S. Ruetz, E. Buchdunger, S. W. Cowan-Jacob, G. Fendrich, J. Liebetanz, *et al.*, Protein kinases as targets for anticancer agents: from inhibitors to useful drugs, *Pharmacol. Therapeut.*, 2002, **93**(2–3), 79–98.
 - 19 M. A. Abdelgawad, R. B. Bakr, O. A. Alkhoja and W. R. Mohamed, Design, synthesis and antitumor activity of novel pyrazolo [3, 4-d] pyrimidine derivatives as EGFR-TK inhibitors, *Bioorg. Chem.*, 2016, **66**, 88–96.
 - 20 M. J. Akhtar, A. A. Khan, Z. Ali, R. P. Dewangan, M. Rafi, M. Q. Hassan, *et al.*, Synthesis of stable benzimidazole derivatives bearing pyrazole as anticancer and EGFR receptor inhibitors, *Bioorg. Chem.*, 2018, **78**, 158–169.
 - 21 W. I. Elsis, R. F. George, Y. M. Syam, G. E. Abd-Ellatef and S. S. Abd El-Karim, Recent achievements in molecular insights, anticancer activities, and comparative structure activity relationships of thiazolidin-4-one derivatives as EGFR inhibitors (2019-present), *Bioorg. Med. Chem.*, 2025, 118244.
 - 22 H. T. Abdel-Mohsen, M. M. Anwar, N. S. Ahmed, S. S. Abd El-Karim and S. H. Abdelwahed, Recent advances in structural optimization of quinazoline-based protein kinase inhibitors for cancer therapy (2021-present), *Molecules*, 2024, **29**(4), 875.
 - 23 K. Komposch and M. Sibilja, EGFR signaling in liver diseases, *Int. J. Mol. Sci.*, 2015, **17**(1), 30.
 - 24 P. Nastaly, S. Stoupiec, M. Popęda, J. Smentoch, T. Schlomm, C. Morrissey, *et al.*, EGFR as a stable marker of prostate cancer dissemination to bones, *Br. J. Cancer*, 2020, **123**(12), 1767–1774.
 - 25 A. A. Romu, Z. Lei, B. Zhou, Z.-S. Chen and V. Korlipara, Design, synthesis and biological evaluation of WZ4002 analogues as EGFR inhibitors, *Bioorg. Med. Chem. Lett.*, 2017, **27**(21), 4832–4837.
 - 26 J. C. Chuang, A. A. Salahudeen and H. A. Wakelee, Rociletinib, a third generation EGFR tyrosine kinase inhibitor: current data and future directions, *Expert Opin. Pharmacother.*, 2016, **17**(7), 989–993.
 - 27 M. R. V. Finlay, M. Anderton, S. Ashton, P. Ballard, P. A. Bethel and M. R. Box, Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations that Spares the Wild Type Form of the Receptor, *J. Med. Chem.*, 2014, **57**(20), 8249–8267.
 - 28 P. A. Jänne, J. C.-H. Yang, D.-W. Kim, D. Planchard, Y. Ohe, S. S. Ramalingam, *et al.*, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, *N. Engl. J. Med.*, 2015, **372**(18), 1689–1699.
 - 29 M. Simons, E. Gordon and L. Claesson-Welsh, Mechanisms and regulation of endothelial VEGF receptor signalling, *Nat. Rev. Mol. Cell Biol.*, 2016, **17**(10), 611–625.
 - 30 P. K. Kopparapu, S. A. Boorjian, B. D. Robinson, M. Downes, L. J. Gudas, N. P. Mongan, *et al.*, Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer, *Anticancer Res.*, 2013, **33**(6), 2381–2390.
 - 31 D. J. LaValley, M. R. Zanotelli, F. Bordeleau, W. Wang, S. C. Schwager and C. A. Reinhart-King, Matrix stiffness enhances VEGFR-2 internalization, signaling, and proliferation in endothelial cells, *Convergent Sci. Phys. Oncol.*, 2017, **3**(4), 044001.
 - 32 R. B. Alnoman, S. Parveen, A. Khan, J. G. Knight and M. Hagar, New quinoline-based BODIPYs as EGFR/VEGFR-2 inhibitors: molecular docking, DFT and in vitro cytotoxicity on HeLa cells, *J. Mol. Struct.*, 2022, **1247**, 131312.
 - 33 A. S. Mostafa, W. A. Bayoumi, M. El-Mesery and A. Elgaml, Molecular design and synthesis of new 3, 4-dihydropyrimidin-2 (1H)-ones as potential anticancer agents with VEGFR-2 inhibiting activity, *Anti-Cancer Agents Med. Chem.*, 2019, **19**(3), 310–322.
 - 34 L. Gong, M. M. Giacomini, C. Giacomini, M. L. Maitland, R. B. Altman and T. E. Klein, PharmGKB summary: sorafenib pathways, *Pharmacogenet. Genom.*, 2017, **27**(6), 240–246.
 - 35 K. R. Flaherty, A. U. Wells, V. Cottin, A. Devaraj, S. L. Walsh, Y. Inoue, *et al.*, Nintedanib in progressive fibrosing interstitial lung diseases, *N. Engl. J. Med.*, 2019, **381**(18), 1718–1727.
 - 36 L. J. Wilmes, M. G. Pallavicini, L. M. Fleming, J. Gibbs, D. Wang, K.-L. Li, *et al.*, AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging, *Magn. Reson. Imaging*, 2007, **25**(3), 319–327.
 - 37 P. Martin, S. Oliver, S.-J. Kennedy, E. Partridge, M. Hutchison, D. Clarke, *et al.*, Pharmacokinetics of vandetanib: three phase I studies in healthy subjects, *Clin. Ther.*, 2012, **34**(1), 221–237.
 - 38 S. H. Hwang, A. T. Weckler, G. Zhang, C. Morisseau, L. V. Nguyen, S. H. Fu, *et al.*, Synthesis and biological evaluation of sorafenib-and regorafenib-like sEH inhibitors, *Bioorg. Med. Chem. Lett.*, 2013, **23**(13), 3732–3737.
 - 39 Y. Dong, H. Hu, Y. Sun, M. Qin, P. Gong, Y. Hou, *et al.*, Design, synthesis and biological evaluation of novel c-Met/HDAC dual inhibitors, *Bioorg. Med. Chem. Lett.*, 2020, **30**(23), 127610.
 - 40 Z. Wang, J. Shi, X. Zhu, W. Zhao, Y. Gong, X. Hao, *et al.*, Design, synthesis and biological evaluation of novel 4-phenoxy pyridine based 3-oxo-3, 4-dihydroquinoline-2-carboxamide derivatives as potential c-Met kinase inhibitors, *Bioorg. Chem.*, 2020, **105**, 104371.
 - 41 M. Mortazavi, E. Raufi, T. Damghani, M. Khoshneviszadeh, N. Edraki, M. Eskandari, *et al.*, Corrigendum to “Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library” [Europ. J. Pharmacol. (2023) 938: 175395], *Eur. J. Pharmacol.*, 2024, **978**, 176777.
 - 42 C.-H. Gow, M.-S. Hsieh, Y.-L. Chen, Y.-N. Liu, S.-G. Wu and J.-Y. Shih, Survival outcomes and prognostic factors of lung cancer patients with the MET exon 14 skipping mutation: a single-center real-world study, *Front. Oncol.*, 2023, **13**, 1113696.



- 43 J. A. Bikker, N. Brooijmans, A. Wissner and T. S. Mansour, Kinase domain mutations in cancer: implications for small molecule drug design strategies, *J. Med. Chem.*, 2009, **52**(6), 1493–1509.
- 44 Jr R. Roskoski, Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update, *Pharmacol. Res.*, 2020, **152**, 104609.
- 45 F. M. Yakes, J. Chen, J. Tan, K. Yamaguchi, Y. Shi, P. Yu, *et al.*, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, *Mol. Cancer Therapeut.*, 2011, **10**(12), 2298–2308.
- 46 B. D. Smith, M. D. Kaufman, C. B. Leary, B. A. Turner, S. C. Wise, Y. M. Ahn, *et al.*, Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2, *Mol. Cancer Therapeut.*, 2015, **14**(9), 2023–2034.
- 47 Y. Dai and D. W. Siemann, BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro, *Mol. Cancer Therapeut.*, 2010, **9**(6), 1554–1561.
- 48 J. K. Rho, Y. J. Choi, S. Y. Kim, T. W. Kim, E. K. Choi, S.-J. Yoon, *et al.*, MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation, *Cancer Res.*, 2014, **74**(1), 253–262.
- 49 Q. Tang, L. Wang, Y. Duan, W. Wang, S. Huang, J. Zhi, *et al.*, Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors, *Eur. J. Med. Chem.*, 2017, **133**, 97–106.
- 50 M. E. Abdelaziz, M. M. El-Miligy, S. M. Fahmy, M. A. Mahran and A. A. Hazzaa, Design, synthesis and docking study of pyridine and thieno [2, 3-b] pyridine derivatives as anticancer PIM-1 kinase inhibitors, *Bioorg. Chem.*, 2018, **80**, 674–692.
- 51 B. H. Naguib, H. B. El-Nassan and T. M. Abdelghany, Synthesis of new pyridothienopyrimidinone derivatives as Pim-1 inhibitors, *J. Enzym. Inhib. Med. Chem.*, 2017, **32**(1), 457–467.
- 52 P. D. Garcia, J. L. Langowski, Y. Wang, M. Chen, J. Castillo, C. Fanton, *et al.*, Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers, *Clin. Cancer Res.*, 2014, **20**(7), 1834–1845.
- 53 M. T. Burger, W. Han, J. Lan, G. Nishiguchi, C. Bellamacina, M. Lindval, *et al.*, Structure guided optimization, in vitro activity, and in vivo activity of pan-PIM kinase inhibitors, *ACS Med. Chem. Lett.*, 2013, **4**(12), 1193–1197.
- 54 P. C. Sharma, K. K. Bansal, A. Sharma, D. Sharma and A. Deep, Thiazole-containing compounds as therapeutic targets for cancer therapy, *Eur. J. Med. Chem.*, 2020, **188**, 112016.
- 55 E. Y. Ahmed, O. M. Abdelhafez, D. Zaafar, A. M. Serry, Y. H. Ahmed, R. F. A. El-Telbany, *et al.*, Antitumor and multikinase inhibition activities of some synthesized coumarin and benzofuran derivatives, *Arch. Pharmazie*, 2022, **355**(6), 2100327.
- 56 S. S. Abd El-Karim, A. H. Mahmoud, A. K. Al-Mokaddem, N. E. Ibrahim, H. M. Alkahtani, A. A. Zen, *et al.*, Development of a New Benzofuran–Pyrazole–Pyridine-Based Molecule for the Management of Osteoarthritis, *Molecules*, 2023, **28**(19), 6814.
- 57 O. A. El-Khouly, M. A. Henen, M. A.-A. El-Sayed and S. M. El-Messery, Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer, *Sci. Rep.*, 2022, **12**(1), 17104.
- 58 T. J. Schumacher, N. Sah, K. Palle, J. Rumbley and V. R. Mereddy, Synthesis and biological evaluation of benzofuran piperazine derivatives as potential anticancer agents, *Bioorg. Med. Chem. Lett.*, 2023, **93**, 129425.
- 59 C. Brullo, F. Rapetti and O. Bruno, Pyrazolyl-ureas as interesting scaffold in medicinal chemistry, *Molecules*, 2020, **25**(15), 3457.
- 60 R. F. Costa, L. C. Turones, K. V. N. Cavalcante, I. A. Rosa Júnior, C. H. Xavier, L. P. Rosseto, *et al.*, Heterocyclic compounds: pharmacology of pyrazole analogs from rational structural considerations, *Front. Pharmacol*, 2021, **12**, 666725.
- 61 G. M. Nitulescu, C. Draghici and O. T. Olaru, New potential antitumor pyrazole derivatives: Synthesis and cytotoxic evaluation, *Int. J. Mol. Sci.*, 2013, **14**(11), 21805–21818.
- 62 G. M. Nitulescu, G. Stancov, O. C. Seremet, G. Nitulescu, D. P. Mihai, C. G. Duta-Bratu, *et al.*, The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies, *Molecules*, 2023, **28**(14), 5359.
- 63 P. Singh and V. Kumar, Special Issue “Hybrid Drugs: Design and Applications”, *Pharmaceuticals*, 2023, **16**(10), 1358.
- 64 R. M. Bokhtia, A. S. Girgis, T. S. Ibrahim, F. Rasslan, E. S. Nossier, R. F. Barghash, *et al.*, Synthesis, antibacterial evaluation, and computational studies of a diverse set of linezolid conjugates, *Pharmaceuticals*, 2022, **15**(2), 191.
- 65 S. S. Panda, M. Thangaraju and B. L. Lokeshwar, Ursolic acid analogs as potential therapeutics for cancer, *Molecules*, 2022, **27**(24), 8981.
- 66 A. L. Flint, D. W. Hansen, L. D. Brown, L. E. Stewart, E. Ortiz and S. S. Panda, Modified curcumins as potential drug candidates for breast cancer: an overview, *Molecules*, 2022, **27**(24), 8891.
- 67 D. Buchanan, A. M. Pham, S. K. Singh and S. S. Panda, Molecular hybridization of alkaloids using 1, 2, 3-triazole-based click chemistry, *Molecules*, 2023, **28**(22), 7593.
- 68 R. M. Mohareb, E. M. Samir and P. A. Halim, Synthesis, and anti-proliferative, Pim-1 kinase inhibitors and molecular docking of thiophenes derived from estrone, *Bioorg. Chem.*, 2019, **83**, 402–413.
- 69 J. Eberhardt, D. Santos-Martins, A. F. Tillack and S. Forli, AutoDock Vina 1.2. 0: new docking methods, expanded force field, and python bindings, *J. Chem. Inf. Model.*, 2021, **61**(8), 3891–3898.
- 70 O. Trott and A. Olson, AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, *J. Comput. Chem.*, 2010, **31**, 455–461.



- 71 M. I. El-Zahar, A. El-Karim, S. Somaia and M. M. Anwar, Synthesis and cytotoxicity screening of some novel benzofuranoyl-pyrazole derivatives against liver and cervix carcinoma cell lines, *S. Afr. J. Chem.*, 2009, **62**, 189–199.
- 72 S. S. Abd El-Karim, M. M. Anwar, N. A. Mohamed, T. Nasr and S. A. Elseginy, Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents, *Bioorg. Chem.*, 2015, **63**, 1–12.
- 73 V. Polshettiwar and R. S. Varma, Microwave-assisted organic synthesis and transformations using benign reaction media, *Acc. Chem. Res.*, 2008, **41**(5), 629–639.
- 74 P. Langer and W. Freiberg, Cyclization reactions of dianions in organic synthesis, *Chem. Rev.*, 2004, **104**(9), 4125–4150.
- 75 M. R. Boyd and K. D. Paull, Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen, *Drug Dev. Res.*, 1995, **34**(2), 91–109.
- 76 R. H. Shoemaker, The NCI60 human tumour cell line anticancer drug screen, *Nat. Rev. Cancer*, 2006, **6**(10), 813–823.
- 77 S. M. Abou-Seri, W. M. Eldehna, M. M. Ali and D. A. Abou El Ella, 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation, *Eur. J. Med. Chem.*, 2016, **107**, 165–179.
- 78 W. S. El-serwy, H. S. Mohamed, W. S. El-serwy, N. A. Mohamed, E. M. Kassem, K. Mahmoud, *et al.*, Thiopyrimidine-5-carbonitrile Derivatives as VEGFR-2 Inhibitors: Synthesis, Anticancer Evaluation, Molecular Docking, ADME Predictions and QSAR Studies, *ChemistrySelect*, 2020, **5**(48), 15243–15253.
- 79 H. E. Hashem, A. E.-G. E. Amr, E. S. Nossier, M. M. Anwar and E. M. Azmy, New benzimidazole-, 1, 2, 4-triazole-, and 1, 3, 5-triazine-based derivatives as potential EGFRWT and EGFR T790M inhibitors: microwave-assisted synthesis, anticancer evaluation, and molecular docking study, *ACS Omega*, 2022, **7**(8), 7155–7171.
- 80 Y. Sun, Y. Liu, X. Ma and H. Hu, The influence of cell cycle regulation on chemotherapy, *Int. J. Mol. Sci.*, 2021, **22**(13), 6923.
- 81 M. S. Nafie, K. Arafa, N. K. Sedky, A. A. Alakhdar and R. K. Arafa, Triaryl dicationic DNA minor-groove binders with antioxidant activity display cytotoxicity and induce apoptosis in breast cancer, *Chem. Biol. Interact.*, 2020, **324**, 109087.
- 82 A. A. Mourad, N. Farouk, E.-S. H. El-Sayed and A. R. Mahdy, EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4-one derivatives, *Life Sci.*, 2021, **277**, 119531.
- 83 D. Shukla, A. M. Alanazi, S. P. Panda, V. D. Dwivedi and M. A. Kamal, Unveiling the antiviral potential of plant compounds from the Meliaceae family against the Zika virus through QSAR modeling and MD simulation analysis, *J. Biomol. Struct. Dyn.*, 2024, **42**(20), 11064–11079.
- 84 R. C. Maloney, M. Zhang, H. Jang and R. Nussinov, The mechanism of activation of monomeric B-Raf V600E, *Comput. Struct. Biotechnol. J.*, 2021, **19**, 3349–3363.
- 85 J. Zhang, P. L. Yang and N. S. Gray, Targeting cancer with small molecule kinase inhibitors, *Nat. Rev. Cancer*, 2009, **9**(1), 28–39.
- 86 C.-H. Yun, K. E. Mengwasser, A. V. Toms, M. S. Woo, H. Greulich, K.-K. Wong, *et al.*, The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**(6), 2070–2075.
- 87 M. McTigue, B. W. Murray, J. H. Chen, Y.-L. Deng, J. Solowiej and R. S. Kania, Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**(45), 18281–18289.
- 88 E. Gherardi, W. Birchmeier, C. Birchmeier and G. V. Woude, Targeting MET in cancer: rationale and progress, *Nat. Rev. Cancer*, 2012, **12**(2), 89–103.
- 89 A. Daina, O. Michielin and V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, *Sci. Rep.*, 2017, **7**(1), 42717.
- 90 C. A. Lipinski, Lead-and drug-like compounds: the rule-of-five revolution, *Drug Discovery Today: Technol.*, 2004, **1**(4), 337–341.
- 91 J. H. Lin and M. Yamazaki, Role of P-glycoprotein in pharmacokinetics: clinical implications, *Clin. Pharmacokinet.*, 2003, **42**, 59–98.

